3 Things You Should Know About Interventional Glaucoma Comanagement

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

Glaucoma is a leading cause of irreversible blindness and affects approximately 80 million people globally, with projections to exceed 111 million by 2040. We know that the elevated intraocular pressure is the key modifiable risk factor which is why reducing intraocular pressure is central to treatment strategies.

In this podcast, expert faculty from the featured symposium at the 2025 EnVision Summit share insights about interventional glaucoma co-management.

Those faculty include ophthalmologists Rachel Simpson from Moran Eye Center in Salt Lake City, UT; James Murphy from Connecticut Eye Physicians in New Haven, CT; Mary Qiu from the Cleveland Clinic’s Cole Eye Institute in Cleveland, Ohio; and optometrist Jessica Steen from the Nova Southeastern University College of Optometry in Fort Lauderdale, FL.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Alcon and Sun Pharmaceutical Industries, Inc.

Faculty:

Rachel Simpson, MD

Glaucoma Specialist
Residency Program Director
Vice Chair of Education
Moran Eye Center
Salt Lake City, UT

Disclosures: Consultant AbbVie, Elios Vision, Glaukos, Nova Eye Medical; Grant Funding: Alcon

James Murphy, MD

Consulting Surgeon
Scarsdale Ophthalmology Associates
Keyhani Eye Associates
Jefferson Valley, NY
Connecticut Eye Physicians
New York and Connecticut
New Haven, CT

Disclosures: Grant/Research Support: Sight Sciences; Consultant; MST, Nextech, Nova Eye Medical, Sight Sciences: Lecturer: Bausch + Lomb, Glaukos, MST, Nova Eye Medical, Sight Sciences, RxSight; Honorarium: MST

Mary Qiu, MD

Associate Program Director
Cole Eye Institute
Cleveland Clinic
Cleveland, OH

Disclosures: Consultant: Nova Eye Medical: Advisory Board: Nova Eye Medical

Jessica Steen, OD, FAAO

Associate Professor
Director, Glaucoma Service
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

Disclosures: Speakers Bureau: Alcon, Allergan, Astellas Pharma, Bausch + Lomb, Carl Zeiss Meditec, Viatris; Advisory Board: Alcon, Allergan, Astellas Pharma, Bausch + Lomb, Carl Zeiss Meditec, Eyenovia, Glaukos, iCare, Ocuphire Pharma, OcuTerra Therapeutics, Opus Genetics, Peripherex, RadiusXR, Santen Pharmaceutical, Viatris; Shareholder: Equinox

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

June 4, 2025

Expiration Date

June 4, 2026